(Q24234614)

1

0 references

Joey Kwong

2

0 references

Zhi Ping Wang

3

0 references

Jinhui Tian

4

0 references

Lei Jiang

5

0 references

Zhong Jin Yue

7

0 references

Jun Qiang Tian

Cochrane Database of Systematic Reviews

8

0 references

publication date

11 May 2011

0 references

published in

0 references

cites work

Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Intravesical chemotherapy and immunotherapy for superficial tumors Basic mechanism of action and future direction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Superficial bladder tumours: analysis of prognostic factors and construction of a predictive index

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Treatment of superficial bladder cancer with intravesical chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Are prostate biopsies mandatory in patients with prostate-specific antigen increase during intravesical immuno- or chemotherapy for superficial bladder cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Superficial bladder cancer: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Superficial bladder cancer T1G3: the choice of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

The health economics of bladder cancer: a comprehensive review of the published literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Mitomycin C: a clinical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Contemporary intravesical treatment options for urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Standard versus hydrophilic catheterization in the adjuvant treatment of patients with superficial bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Bladder cancer--resection/ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Squamous cell carcinoma of the bilharzial and non-bilharzial urinary bladder: a review of etiological features, natural history, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Trial with bacillus Calmette-Guérin and epirubicin combination in the prophylaxis of superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Improving efficacy of intravesical chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Actual experience and future development of gemcitabine in superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Recent advances in the treatment of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Superficial bladder cancer: part 2. Management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Complications of intravesical therapy for urothelial cancer of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Updated concepts and treatment of carcinoma in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Bladder cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Effect of intravesical instillation on performance of uCYT+ test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Systemic chemotherapy for patients with advanced and metastatic bladder cancer: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Advances in intravesical therapy of urinary bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Current problems and needs in the treatment of pT1 G3 bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Re: Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Intravesical therapy of superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

The use of valrubicin for the chemoresection of superficial bladder cancer -- a marker lesion study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

A systematic overview of chemotherapy effects in urothelial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Combined bacillus Calmette-Guerin and interferon use in superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Is intravesical chemotherapy for superficial bladder cancer still justified?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Epirubicin: a review of its intravesical use in superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

The management of superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Low-grade Ta (noninvasive) urothelial carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

The current status of intravesical therapy for superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Current and new strategies in immunotherapy for superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Potential of interferon-alpha in solid tumours: part 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Will a new intravesical chemotherapy agent improve the treatment of non-muscle-invasive bladder cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Re: Can early single dose instillation of epirubicin improve bacillus calmette-guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study: T. Cai, G. Nesi, G. T

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Current recommendations for the management of bladder cancer. Drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Management of superficial bladder cancer with intravesical chemotherapy: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Intravesical gemcitabine: a phase 1 and pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

A prospective cohort study of bladder cancer risk in relation to active cigarette smoking and household exposure to secondhand cigarette smoke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Intravesical therapy for bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Guidelines on bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Optimal treatment for intermediate- and high-risk, nonmuscle-invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Current status of intravesical chemotherapy trials in the EORTC Urological Group. An overview

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

[Bladder cancer--what's new]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Prognostic parameters in superficial bladder cancer: an analysis of 315 cases

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

The Side Effects of Bacillus Calmette-Guerin in the Treatment of Ta T1 Bladder Cancer Do Not Predict its Efficacy: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Genitourinary cancers in older adults.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Intravesical therapy of superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Differential C-erbB-2 and VEGF expression following BCG immunotherapy in superficial papillary transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

New treatment approaches for superficial and invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Intravesical chemotherapy for superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

The management of superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Analysis of prognostic factors related to primary superficial bladder cancer tumor recurrence in prophylactic intravesical epirubicin therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Clinical experience with BCG alone versus BCG plus epirubicin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

The management of superficial bladder cancer: an interactive seminar.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Phase II trials in Ta, T1 bladder cancer. The marker tumour concept.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Transitional cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

1 reference

7 January 2021

Combined immunochemotherapy (CEP, M-VEP + BCG) in the treatment of invasive bladder tumors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Neoadiuvant treatment with intravesical interleukin-2 for recurrent superficial transitional bladder carcinoma Ta-T1/G1-2

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

1 reference

7 January 2021

The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Management of bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Cytological changes induced by intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Effect of intravesical instillations on the human complement factor H related protein (BTA stat) test

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Improved patient outcomes with BCG immunotherapy vs. chemotherapy - Swedish and worldwide experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Intravesical bacillus Calmette-Guérin versus epirubicin in the prophylaxis of recurrent and/or multiple superficial bladder tumours

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Intravesical chemoresection with 4'-epi-doxorubicin in patients with superficial bladder tumors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

4'-Epidoxorubicin versus Mitomycin C Intravesical Chemoprophylaxis of Superficial Bladder Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

BCG immunotherapy for superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Risk factors for bladder cancer.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

Urinary zinc levels in patients with superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

[Superficial urinary bladder tumors treatment results--a 10-year experience]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006885.PUB2

7 January 2021

10.1002/14651858.CD006885.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

release_5vrus47vk5gnteh5w6tqejm32u

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/5vrus47vk5gnteh5w6tqejm32u

24 November 2022

mapped directly with Wikidata item

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

21563157

1 reference

Consolidated OpenCitations Corpus – April 2017